August 9, 2016 / 10:22 AM / a year ago

BRIEF-Pharming Group announces acquisition of all North American commercialisation rights to Ruconest from Valeant

1 Min Read

Aug 9 (Reuters) - Pharming Group NV :

* Announces acquisition of all North American commercialisation rights to Ruconest from Valeant

* $125 million deal value, with an upfront fee for Valeant of US$60 million, and self-funding sales milestone payments up to a further US$65 million in total

* Funding through a combination of straight debt and new equity capital of between US$ 80-100 million Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below